Althea Group (AGH.AX)

Overall impact
C (41)

Commentary

Althea Group is an average overall performer. With a 'C' rating of 41.3 for overall impact (26th percentile compared to all companies), Althea Group ranks 247th out of 255 industry peers, behind Catalyst Pharmaceuticals, Agios Pharmaceuticals, Pharmaron Beijing H and 243 others, and ahead of Perrigo, FIS, Viatris and 5 others. On top material causes for Althea Group's industry (Pharmaceuticals), Althea Group performs well in Child and Maternal Health (95.0 score), Accountable Institutions (94.7), Child and Maternal Health (93.3) and 54 other causes where it received an 'A' score and performs poorly in Accountable Institutions (35.3 score), Accountable Institutions (12.4), Racial Justice and Civil Rights (0.0) and 48 other causes where it received a 'D' or 'F' score.
Screens
Fur
Impact
Cause AGH.AX
Peer rank
Overall impact

Log in to view this information

Screens
Fur
Impact trend

Change in rating for overall impact

Log in to view this information

Company
Founded
2014
Employees
1,546
Sector
Health Care
Industry
Pharmaceuticals
Sub-industry
Pharmaceuticals
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
Vic, Australia
Share classes
AGH.AX
Description
Althea Group Holdings Limited manufactures, distributes, and sells cannabis-based medicines and recreational cannabis products in Australia, the United Kingdom, Canada, Germany, and Ireland. It also offers education, access, and management services to support eligible patients and healthcare professionals in navigating medicinal cannabis treatment pathways. In addition, the company provides formulation and manufacturing of recreational cannabis products, such as beverages, edibles, concentrates, and topicals; and owns and operates a private medical cannabis clinic network under the MyAccess Clinics name. Althea Group Holdings Limited was founded in 2016 and is based in Melbourne, Australia.
Material causes
Ethos considers the following causes material for Althea Group, based on its industry sub-industry Pharmaceuticals. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.